Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

alanosine

An amino acid analogue and antibiotic derived from the bacterium Streptomyces alanosinicus with antimetabolite and potential antineoplastic activities. L-alanosine inhibits adenylosuccinate synthetase, which converts inosine monophospate (IMP) into adenylosuccinate, an intermediate in purine metabolism. L-alanosine-induced disruption of de novo purine biosynthesis is potentiated by methylthioadenosine phosphorylase (MTAP) deficiency. The clinical use of this agent may be limited by its toxicity profile. MTAP is a key enzyme in the adenine and methionine salvage pathways.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:L-alanosine sodium
Code name:SDX-102
Chemical structure:3-(hydroxynitrosoamino)-L-alanine
L-2-amino-3-(hydroxynitrosoamino)propionic acid
L-2-amino-3-[(N-nitroso)hydroxylamino]propionic acid
IND number:14247
NSC code:153353
529469
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search